BiME® - Bispecific Macrophage Engager
BiME®: Unlocking the Power of Macrophages in Cancer Immunotherapy
What is BiME®?
BiME® (Bispecific Macrophage Engager) is a groundbreaking bispecific antibody-based platform designed to activate macrophages and enhance their tumor-killing power.
Tumor cells evade immune destruction by exploiting a “don’t-eat-me”signal which interacts with SIRPα on macrophages to block phagocytosis. BiME® disrupts this mechanism while simultaneously directing macrophages to attack tumors.
How BiME® Works?
✔ Blocks the “don’t-eat-me” signal – The SIRPα-targeting antibody prevents CD47 from sending inhibitory signals to myeloid.
✔ Delivers an “eat-me” signal – The tumor-associated antigen (TAA)-targeting antibody binds to cancer cells, activating myeloid cells through Fc receptor engagement.
✔ Boosts tumor cell phagocytosis – Triggers strong myeloid cell phagocytosis leading to direct tumor cell elimination.
✔ Reprograms the TME – Converts suppressive TAMs into M1-like macrophages for a sustained anti-tumor response.
✔ Up to phagocytosis, myeloid cells present tumor antigens to T cells activating T cells which leads to eventual tumor killing.
With its unique dual-targeting approach, BiME® turns tumors from immune-resistant (“cold”) into immune-responsive (“hot”), unlocking new treatment possibilities.
Why is BiME® a Game-Changer?
Broad Applications Across Solid and Blood Cancers
BiME® technology is designed to address a wide range of malignancies, offering therapeutic potential across both solid tumors and hematologic cancers.
Enhanced Safety Profile
Unlike many T-cell therapies, BiME® significantly reduces the risk of cytokine storms—one of the major safety concerns associated with T-cell engager (TCE)-based treatments.